Stock Ratings / Health Care / AQST / forecast

OCS (58) PHAT (46) INDP (36) DMAC (34) ⌘ Pro Terminal →

Aquestive Therapeutics Inc. (AQST) 12-Month Stock Forecast & Price Target Cone

$4.04 -4.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Aquestive Therapeutics Inc. (AQST) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $507.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AQST)Realized 20D OHLCV Swing Band: ±11.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your AQST Position Size: $10,000

Shares at $4.04: 2475.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.71

$6,708

$-3,292 (-32.9%)

12M Consensus BaseTarget $3.48

$8,614

$-1,386 (-13.9%)

12M Bull Case BreakoutTarget $7.19

$17,797

+$7,797 (+78.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$7	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AQST)

✓Walkthrough of AQST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AQST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.46%▲ ASCENDING CHANNEL

2026-10-30O $4.01H $4.05L $3.86C $4.04VOL 2.42M

RES: $5.73SUP: $3.66SMA50: $4.66SMA200: $4.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AQST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AQST Butterfly Map → + Track AQST →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -22.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AQST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AQST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AQST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AQST)

Health Care Rank #976 of 1016 ⚔️ OCS vs AQST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AQST vs. OCS, PHAT, INDP, DMAC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aquestive Therapeutics Inc. (AQST) ranks #976 by composite RQD confidence (27/100, grade E) and #449 by equity capitalization ($507.1M). Within this direct 5-issuer industry benchmark cohort, AQST leads on earnings valuation at N/A trailing P/E, while AQST leads on capital efficiency and profitability with -35.0% ROIC and 58.3% gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with AQST at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AQST ACTIVE Aquestive Therapeutics Inc.	E	27/100	—	58.3%	-35.0%	-4.49%	$507.1M	Benchmark Subject
OCS Oculis Holding AG	D+	58/100	—	—	—	+3.26%	$507.5M	/ocs-vs-aqst →
PHAT Phathom Pharmaceuticals Inc.	D	46/100	—	87.1%	-35.0%	-0.95%	$503.2M	/phat-vs-aqst →
INDP Indaptus Therapeutics Inc.	D-	36/100	—	—	-35.0%	+0.30%	$513.0M	/indp-vs-aqst →
DMAC DiaMedica Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.05%	$513.4M	/dmac-vs-aqst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001398733

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aquestive Therapeutics Inc. (AQST) reported GAAP revenue of $44.5M (-22.6% vs. FY2024 revenue of $57.6M , and -11.9% cumulative change since FY2023) , GAAP net income of -$83.8M, operating cash flow of -$52.4M, and free cash flow of -$53.0M (-47.5% YoY). On the balance sheet, AQST closed FY2025 with $160.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$44.5M	-$83.8M	-$52.4M	-$53.0M	$160.4M	—
FY2024 (FY)	2024-12-31	$57.6M	-$44.1M	-$35.8M	-$35.9M	$101.4M	—
FY2023 (FY)	2023-12-31	$50.6M	-$7.9M	-$6.4M	-$6.4M	—	—

3. AQST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AQST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aquestive Therapeutics Inc. (NASDAQ: AQST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $4.04 (-4.49% 1D, market cap $507.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AQST ranks #976 in composite RQD confidence.

How does AQST compare to OCS and PHAT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AQST carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, OCS (Oculis Holding AG) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $507.5M) and PHAT (Phathom Pharmaceuticals Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $503.2M). Among the 5-stock peer group, AQST leads on earnings multiple (N/A) while AQST leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AQST?

Per AQST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001398733), Aquestive Therapeutics Inc. generated $44.5M in revenue (-22.6% YoY), -$83.8M in net income, and -$53.0M in free cash flow against $160.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AQST trading relative to its 50-day, 200-day, and 52-week technical levels?

AQST last traded at $4.04 (-4.49% on volume of 2,018,407 shares), positioning the stock -13.30% below its 50-day simple moving average ($4.66) and -4.04% below its 200-day simple moving average ($4.21). Across its 52-week range of $2.93 to $6.85, AQST sits at the 28.3% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.5% ($3.58 to $4.50).

AQST Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AQST's 12-month stock price target?

Aquestive Therapeutics Inc. (AQST) carries a 12-month consensus base price target of $3.48 (-13.9% from $4.04), with a bull-case target of $7.19 and a bear-case floor of $2.71.